SP-MHCI-0380-2

Human TARP 27-35, FVFLRNFSL

US$169.00

In stock

Description

About Human TARP 27-35, FVFLRNFSL

The Human T-cell receptor gamma alternate reading frame protein Peptide (IEDB: 18159) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The T-cell receptor gamma alternate reading frame protein Peptide, H-FVFLRNFSL-OH (Uniprot: A2JGV3 aa: 27-35) from JPT is produced under strict quality control and quality management.

Human TARP 27-35, FVFLRNFSL - Specifications

  • Peptide sequence: H-FVFLRNFSL-OH
  • Amount: 1 mg
  • Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
  • Counterion: TFA
  • Delivery Format: Freeze-dried in glass vial
  • Application(s): T-cell Immunity
  • Condition(s)/Topic(s): Prostate cancer, Breast cancer
  • Standard Delivery Time: approx. 3 weeks

JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Request a Quote for you custom antigen peptide!

Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!

References

References for Human TARP 27-35, FVFLRNFSL

References:
Read References with JPT’s Antigen Peptides
Human TARP 27-35, FVFLRNFSL has been described in:
Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP., Prostate, 2004 (PMID: 15305339)
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer., Oncoimmunology, 2016 (PMID: 27622067)
CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells., J Immunol, 2000 (PMID: 10861098)

Documentation

Documentation for Human TARP 27-35, FVFLRNFSL

Properties

Properties of Human TARP 27-35, FVFLRNFSL

Properties Values
Application: T-cell immunity
Category: Antigen Peptides
Condition / Topic: Breast cancer, Prostate cancer
Layout: Freeze-dried in glass vial
Organism: Human
Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
Quantification: No, Yes

Further Information to Human TARP 27-35, FVFLRNFSL

Information Values
Sequence: H-FVFLRNFSL-OH
Specifications: 9mer peptide as TFA salt
Loading...

Check our list of products, click and go.

Get a quote